The Company

Background

Epiterapia Inc. was founded in 2016 by Moshe Szyf, a leading world pioneer in the exciting and rapidly emerging science of Epigenetics.

A Canadian company, dedicated to harnessing the untapped power and possibilities of Epigenetics (with its research and diagnostic lab in Hong Kong), epiterapia is planning to expand operations by establishing “next generation” genetic diagnostic labs in several countries.

PS_shoot_epiterapia_gallery-164.jpg

Mission

With an emphasis on the evolving markets in Euro-Asia and our immediate focus on tests, prevention and early treatment for common diseases, our mission is to positively impact the healthcare, well-being and very quality of life for large populations of people, world-wide.  

Simply stated, the science of Epigenetics centers on DNA Methylation (a simple biochemical process) that changes a mark on your DNA when cancer or other catastrophic diseases may develop.

While the company is new, Szyf’s three decades of ground-breaking research and cutting-edge innovations in Epigenetics — how it occurs and how it is passed from generation to generation — has already disrupted medical science with its potential to detect, diagnose, prevent or cure diseases.

Epiterapia believes the ability to measure and diagnose these changes in DNA will not only revolutionize the impact on fighting disease but on regulating our critical cardiovascular, neurological, reproductive, and detoxification systems as well.

We believe that integrating our novel diagnostics into these developing markets will greatly affect the quality of health care for the people of these countries. We are interested in building diagnostic licensing partnerships in this area, as they become available.

We invite you to contact us for more information. Join our mission to be a major force in the explosive new science of Epigenetics by becoming a partner and an influencer in global healthcare.


Moshe Szyf

Moshe-unedited.jpg

Dr. Moshe Szyf is a leading-edge force in the emerging science of Epigenetics. With a Ph.D from the celebrated Hebrew University, a postdoctoral fellowship in Genetics at Harvard Medical School, a Professorship at McGill University and a Chair in Pharmacology at GlaxoSmithKline, Dr. Szyf is a “pioneer powerhouse” in the industry.

McGill ranks #1 in Canada, among medical-doctoral universities, and Szyf is keeping the best company among the Hebrew University’s first Board of Governors: Albert Einstein, Sigmund Freud and Chaim Weizman.

But Szyf is not known for the company he keeps. Szyf is renowned for three decades of his revolutionary research in genetics, early cancer detection and presenting the first evidence that our genetic makeup is not fixed at birth. Rather, according to Szyf, our genetic code may be changed by a biochemical process called DNA Methylation.

DNA is not just a static, written script. DNA is a dynamic movie, running as our experiences are being written.
— Moshe Szyf

These changes, passed from one generation to the next, are influenced by our experiences, environment and lifestyle behaviours; they have the power to change our basic biology. “DNA is not just a static, written script,” Szyf says, “DNA is a dynamic movie, running as our experiences are being written.”

Szyf has published nearly 300 peer-reviewed papers, is the founder and first chief editor of the first journal in the field of Epigenetics, associate editor of Clinical Epigenetics, and is part of the Editorial Board of the Environmental Epigenetics journal.

Dr. Szyf is also the founding co-director of the Sackler Institute for Epigenetics and Psychobiology at McGill and founder of both epiterapia and the research lab, HKG Epitherapeutics.

Along with his lifelong commitment to uncovering hypotheses and then making them work, Szyf still carves out the time to share his groundbreaking innovations by contributing to the widely-popular, highly-respected TED talks which are viewed 1.5 million times a day.

For Dr. Moshe Szyf, Epigenetics and DNA methylation leads to his ultimate mission: “to translate our understanding of Epigenetics into new products for early detection of disease. The true horizons of medicine lie in predicting and eliminating disease before it consumes us.”

With upcoming products in early cancer detection and battling addiction, Dr. Szyf says, “Success for our products means not only helping people avoid disease, but guiding lifestyle changes that may prevent the disease and enhance their youth and well being.”